Compare CEPU & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | VERA |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2018 | 2021 |
| Metric | CEPU | VERA |
|---|---|---|
| Price | $17.38 | $46.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $17.50 | ★ $76.60 |
| AVG Volume (30 Days) | 260.9K | ★ 1.5M |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $607,552,200.00 | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | $15.36 | N/A |
| P/E Ratio | $13.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.43 | $18.53 |
| 52 Week High | $18.50 | $56.05 |
| Indicator | CEPU | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 53.97 |
| Support Level | $16.86 | $47.22 |
| Resistance Level | $17.95 | $56.05 |
| Average True Range (ATR) | 0.71 | 2.35 |
| MACD | -0.11 | -1.00 |
| Stochastic Oscillator | 70.24 | 9.63 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.